CVac

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article reads like a press release or a news article and may be largely based on routine coverage. Please help improve this article and add independent sources. (December 2015) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (December 2015) (Learn how and when to remove this message) (Learn how and when to remove this message)

CVac (short for Cancer Vaccine), is an immunotherapeutic agent that was 1st developed in Australia.

CVac was developed by the biotechnology company Prima BioMed (Nasdaq: PBMD) through to Phase II clinical studies between 2001 and 2015. After inconclusive clinical data in ovarian cancer 2013 and 2014, Prima announced in February 2015 that it had ceased recruiting into CVAc clinical studies and was seeking commercial partners for the product.^[1]